Novartis Eyes $1B Sales With Fda Nod For Targeted Sickle Cell Disease Drug Adakveo
Another Candidate For Novartis' Future Blockbuster Club Is Here.Friday, The Swiss Drugmaker Won Fda Approval For Adakveo, The First Targeted Therapy To Prevent The Painful Vaso-Occlusive Crises (Vocs) That Come Along With Sickle Cell Disease. The Nod Came Weeks Ahead Of Schedule, Even On Top Of A Priority Review Doled Out In July.Novartis Has Priced The New Drug, Meant For Patients 16 And Older, At A Wholesale Acquisition Cost (Wac) Of $2,357 Per Vial. As It
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
